Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 4/2013

01-08-2013 | Case Report

Eosinophilia associated with bupropion

Authors: Montserrat García, Borja Ruiz, Carmelo Aguirre, Esther Etxegarai, Unax Lertxundi

Published in: International Journal of Clinical Pharmacy | Issue 4/2013

Login to get access

Abstract

Case (description)

A 48-year-old woman started treatment with bupropion 150 mg once daily for depressive symptoms. After 19 days she presented to her family physician complaining of myalgia and non-productive cough. The physical examination was normal and laboratory investigations showed an eosinophil count of 4.7 × 109/L (0–0.5). The results of a basal test before to bupropion intake were within normal range including eosinophils (0.2 × 109/L). After ruling out other causes of eosinophilia, the physician decided to gradually discontinue bupropion, and a marked decrease in absolute eosinophil count was subsequently observed.

Conclusion

To the best of our knowledge, this is the third published case of bupropion-related eosinophilia. Although, in light of the case presented, the prevalence of this adverse effect seems to be low, an awareness that bupropion can be a potential cause of eosinophilia may lead to the avoidance of unnecessary diagnostic tests or referral to other specialists.
Literature
2.
go back to reference Bupropion. DRUGDEX System. Greenwood Village, CO: Thomson Micromedex. Accessed 19 Dec 2012. Bupropion. DRUGDEX System. Greenwood Village, CO: Thomson Micromedex. Accessed 19 Dec 2012.
3.
go back to reference Malesker MA, Soori GS, Malone PM, Mahowald JA, Housel GJ. Eosinophilia associated with bupropion. Ann Pharmacother. 1995;29:867–9.PubMed Malesker MA, Soori GS, Malone PM, Mahowald JA, Housel GJ. Eosinophilia associated with bupropion. Ann Pharmacother. 1995;29:867–9.PubMed
4.
go back to reference Bagshaw SM, Cload B, Gilmour J, Leung ST, Bowen TJ. Drug-induced rash with eosinophilia and systemic symptoms syndrome with bupropion administration. Ann Allergy Asthma Immunol. 2003;90:572–5.PubMedCrossRef Bagshaw SM, Cload B, Gilmour J, Leung ST, Bowen TJ. Drug-induced rash with eosinophilia and systemic symptoms syndrome with bupropion administration. Ann Allergy Asthma Immunol. 2003;90:572–5.PubMedCrossRef
5.
go back to reference Weller PF. Approach to the patient with eosinophilia. In: Mahoney DH, Bochner BS, editors. UpToDate. UpToDate: Waltham, MA; 2012. Weller PF. Approach to the patient with eosinophilia. In: Mahoney DH, Bochner BS, editors. UpToDate. UpToDate: Waltham, MA; 2012.
7.
go back to reference Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med. 2011;124(7):588–97.PubMedCrossRef Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med. 2011;124(7):588–97.PubMedCrossRef
9.
go back to reference Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.PubMedCrossRef Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.PubMedCrossRef
10.
go back to reference Mejia R, Nutman TB. Evaluation and differential diagnosis of marked, persistent eosinophilia. Semin Hematol. 2012;49(2):149–59.PubMedCrossRef Mejia R, Nutman TB. Evaluation and differential diagnosis of marked, persistent eosinophilia. Semin Hematol. 2012;49(2):149–59.PubMedCrossRef
Metadata
Title
Eosinophilia associated with bupropion
Authors
Montserrat García
Borja Ruiz
Carmelo Aguirre
Esther Etxegarai
Unax Lertxundi
Publication date
01-08-2013
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 4/2013
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-013-9803-y

Other articles of this Issue 4/2013

International Journal of Clinical Pharmacy 4/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.